HEB



JOHP

Journal of Hospital Pharmacy

An Official Publication of Bureau for Health & Education Status Upliftment (Constitutionally Entitled as Health-Education, Bureau)

REVIEW ON MUCORMYCOSIS: A RARE BUT LIFE-THREATENING EPIDEMIC DURING COVID -19 PANDEMIC

*¹Anjuna Prakashan, ² Saisudha Sekar, ³Dr. Senthil Rajan

Department of Pharmaceutics, Swami Vivekanandha College of Pharmacy, Tiruchengode-637205 Tamilnadu, India

^{*1,2} Assistant Professor, Department of Pharmaceutics, Swami Vivekanandha College of Pharmacy, Tiruchengode-637205, The TN Dr.M.G.R, Medical University Tamilnadu, India.

³ Professor & Head, Department of Pharmaceutics, Swami Vivekanandha College of Pharmacy, Tiruchengode-637205, The TN Dr.M.G.R, Medical University Tamilnadu, India

Corresponding author:

Anjuna Prakashan, Assistant Professor, Swami Vivekanandha College of Pharmacy, Tiruchengode, Erode, Tamilnadu, India, Pin code: 637205

Email id: serviceheb@gmail.com

ABSTRACT

Mucormycosis is an uncommon but deadly fungal infection caused by the inhalation of mucromycetes, a form of fungus. Mucormycosis is more frequent among persons who have a weakened immune system, diabetes, or are using corticosteroid treatment, according to clinical evidence. COVID-19 patients who have high blood sugar levels and are using immunosuppressants have a higher risk of infection, according to new research. There are just three anti-Mucor treatments available: Amphotericin B, Isavuconazole, and Posaconazole. Surgical debulking is the sole option if the situation worsens. These illnesses are extremely lethal, and most people will die if they are not treated properly. The death rate varies between 25% and 90%. The rate of brain death is extremely high once the virus has reached the brain. Hence a lot of emphasis is given to early diagnosis and timely treatment.

KEYWORDS: Mucormycosis, COVID-19, Amphotericin B, diabetes, corticosteroid

Access this Article Online	Quick Response Code:
Website: http://www.journalofhospitalpharmacy.in	
Received on 01/03/2022	
Accepted on 18/03/2022 © HEB All rights reserved	